Myriad Genetics Inc (MYGN)
Profitability ratios
Return on sales
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 19.88% | 14.68% | 4.32% | 0.52% | -26.04% | -18.36% | 2.49% | 14.29% | 38.72% | 33.04% | 30.31% | 27.34% | 0.02% | 1.86% | -17.35% | -11.18% | -5.77% | 5.80% | 23.14% | 25.16% |
| Operating profit margin | -14.17% | -19.61% | -30.41% | -34.53% | -38.03% | -37.79% | -24.17% | -20.82% | -16.02% | -20.02% | -20.17% | -22.51% | -28.07% | -29.72% | -51.08% | -42.69% | -36.90% | -22.53% | -3.67% | -1.76% |
| Pretax margin | -14.27% | -19.70% | -30.73% | -35.18% | -38.55% | -38.06% | -24.11% | -20.82% | -16.09% | -5.77% | -4.04% | -6.75% | -8.60% | -26.35% | -50.11% | -41.70% | -35.55% | -22.99% | -4.74% | -2.80% |
| Net profit margin | -14.19% | -19.52% | -30.61% | -35.32% | -37.51% | -35.65% | -21.13% | -16.59% | -9.42% | -2.12% | -0.98% | -3.21% | -5.22% | -19.45% | -39.92% | -33.09% | -31.77% | -19.77% | -3.27% | -1.86% |
Myriad Genetics Inc's profitability ratios have shown significant fluctuations over the reported periods. The gross profit margin has ranged from negative figures to around 40%, with a recent improvement to almost 20% in the latest quarter.
However, the operating profit margin has consistently been negative, indicating challenges in controlling operational costs and generating profits from core business activities. The pretax margin has also been consistently negative, suggesting difficulties in managing pre-tax income relative to revenue.
Moreover, the net profit margin has shown a similar trend of negativity, with a recent improvement to around -14%. This indicates that after considering all expenses, including taxes, the company is still making losses but has managed to decrease the extent of the losses in the latest period.
Overall, Myriad Genetics Inc's profitability ratios reflect a mixed performance with recent improvements in gross profit margin but ongoing challenges in operating profit and net profit, highlighting the need for the company to focus on cost management and revenue generation strategies.
Return on investment
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -10.71% | -14.37% | -20.99% | -22.45% | -24.21% | -22.16% | -14.30% | -11.73% | -10.85% | -13.75% | -13.49% | -14.42% | -14.00% | -12.89% | -21.56% | -17.33% | -16.50% | -11.68% | -1.86% | -0.91% |
| Return on assets (ROA) | -10.73% | -14.30% | -21.13% | -22.97% | -23.88% | -20.91% | -12.50% | -9.34% | -6.38% | -1.45% | -0.65% | -2.06% | -2.60% | -8.44% | -16.85% | -13.44% | -14.20% | -10.25% | -1.66% | -0.96% |
| Return on total capital | -14.70% | -19.70% | -29.12% | -31.56% | -38.66% | -33.91% | -19.64% | -15.51% | -14.10% | -4.74% | -3.09% | -5.22% | -4.99% | -16.01% | -31.02% | -25.71% | -18.59% | -13.54% | -2.01% | -0.79% |
| Return on equity (ROE) | -15.85% | -20.96% | -30.87% | -33.62% | -40.15% | -33.76% | -17.50% | -12.64% | -8.43% | -1.86% | -0.86% | -2.81% | -3.59% | -12.72% | -25.74% | -21.35% | -21.73% | -15.33% | -2.43% | -1.42% |
Myriad Genetics Inc's profitability ratios have shown a declining trend over the periods analyzed.
The Operating Return on Assets (Operating ROA) has ranged from -24.21% to -10.71%, indicating that the company's operating income generated from its assets has been negative, with a significant decrease seen in recent periods.
Similarly, the Return on Assets (ROA) has fluctuated between -23.88% and -0.65%, remaining negative throughout. This signifies that Myriad Genetics Inc has not been able to generate a positive return on its assets during the periods analyzed.
The Return on Total Capital has shown a downward trend, ranging from -38.66% to -14.10%. This ratio reflects the company's ability to generate profits from all sources of capital invested in the business, and the decreasing values indicate a decline in overall profitability.
Furthermore, the Return on Equity (ROE) has varied between -40.15% and -1.42%, reflecting a negative return for the shareholders. This ratio highlights the company's ability to generate profits from shareholder investments, and the declining trend suggests a decrease in shareholder value over the periods analyzed.
Overall, Myriad Genetics Inc's profitability ratios depict a challenging financial situation characterized by negative returns and decreasing profitability over the analyzed periods.